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Abstract
This article presents the role of the hypothalamus in reproduction, the definition of hypogonadotropic hypogonadism (HH), and the causes 
of acquired and syndromic HH and idiopathic HH (IHH). The authors present a short review of major causes of acquired HH, but most 
of the causes of IHH will not be discussed because they do not fall within the scope of the article. More attention is devoted to idiopathic 
HH, especially the genetic basis of IHH. Also presented in the article are clinical criteria of CHARGE syndrome. Later, the article discusses 
the clinical presentation, establishing the diagnosis, and management of IHH. The article ends with a brief overview of nutritional hypo-
thalamic dysfunction and athletic amenorrhea. (Pol J Endocrinol 2011; 62 (6): 560–567)
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Streszczenie
Artykuł przedstawia rolę podwzgórza w reprodukcji, definicję hipogonadyzmu hipogonadotropowego (HH), przyczyny nabytego 
i systemowego HH oraz idiopatycznego HH. Autorzy prezentują krótki przegląd najważniejszych przyczyn nabytego HH, ale większość 
nie została omówiona, ponieważ nie wchodzą w zakres tego artykułu. Więcej uwagi poświęcono idiopatycznemu HH, szczególnie jego 
genetycznym podstawom. Przedstawiono kliniczne kryteria zespołu CHARGE. Omówiono również kliniczne objawy, ustalanie roz-
poznania oraz postępowanie w IHH. Artykuł kończy się krótkim przeglądem żywieniowych zaburzeń podwzgórza i braku miesiączki 
u młodocianych stosujących intensywny trening fizyczny. (Endokrynol Pol 2011; 62 (6): 560–567)
Słowa kluczowe: hipogonadyzm hipogonadotropowy, gonadoliberyna (GnRH), zespół Kallmanna
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Introduction
During the last decade, the rapidly expanding fields 
of molecular biology and genetics have allowed us to 
better understand the clinical symptoms of endocrine 
disorders, including menstrual cycle disturbances at 
reproductive age.
The role of the hypothalamus 
in reproduction
Hypothalamic nuclei secrete gonadotropin-releasing 
hormone (GnRH), which is the primary regulator 
of reproductive function. The pulsatile nature of 
hypothalamic GnRH release determines episodic 
pituitary secretion. The periodicity and amplitude of 
the pulsatile rhythm of GnRH/gonadotropin secretion 
are crucial in the entire reproductive axis. The fact 
that GnRH plays a critical role in the feedback regula-
tion of gonadotropin secretion has been known for 
many years. But the neural mechanism of its action 
remains unclear. Intensive investigations over the past 
seven years strongly suggest that sex steroid feedback 
regulation of GnRH cells is predominantly exerted via 
kisspeptin cells, although many other cell types in the 
brain also play a role [1].
GnRH acts as a primary stimulus for gonadotro-
pin release. An optimal frequency of GnRH pulsatile 
stimulation of the gonadotropes is essential to maintain 
appropriate plasma levels of luteinising hormone (LH) 
and follicle-stimulating hormone (FSH). The circulating 
gonadotropins decline when the frequency of GnRH 
pulses is too low, and also when GnRH stimulation 
is too frequent or continuous. Different GnRH pulse 
frequencies have been found to participate in the regula-
tion of LH b and FSH b gene expression. Interestingly, 
an increase in GnRH pulse frequency favours LH b 
gene expression, while a decrease favours FSH b gene 
expression [2]. In addition to GnRH, regulation of the 
activin/follistatin/inhibin feedback loop is thought to be 
important for differential LH b and FSH b synthesis. The 
main roles which gonadotropins play are the regulation 
and control of sex differentiation and gonadal function, 
namely gametogenesis and steroidogenesis. Hypogo-
561
Endokrynologia Polska/Polish Journal of Endocrinology 2011; 62 (6)
SZ
K
O
LE
N
IE
PO
D
Y
PL
O
M
O
W
E
nadotropic hypogonadism occurs when GnRH neurons 
are damaged.
Definition of hypogonadotropic 
hypogonadism
Hypogonadotropic hypogonadism (HH) is charac-
terised by absent or decreased function of the female 
ovaries. It can be defined by inappropriately low se-
rum concentrations of LH and FSH, which is an effect 
of GnRH deficiency. HH is most frequently acquired 
and caused by a number of pathological processes, 
but it can also occur as part of various congenital syn-
dromes. Genetic causes of central hypogonadism have 
been identified. Idiopathic or isolated HH (IHH) was 
then used to indicate cases in which secondary causes 
of HH had been excluded.
Acquired and syndromic causes of HH
Acquired and syndromic causes of HH include the fol-
lowing: CNS or pituitary tumours, infiltrative diseases, 
infection, brain/pituitary radiation, pituitary apoplexy, 
head trauma, drugs (GnRH agonists/antagonists, 
glucocorticoids, narcotics, chemotherapy), functional 
deficiency resulting from chronic systemic illness, eat-
ing disorders, hypothyroidism, hyperprolactinemia, 
diabetes mellitus, and Cushing’s disease.
Hypogonadotropic hypogonadism may be present 
in hypothyroidism. Pituitary sensitivity to GnRH may 
be reduced in hypothyroid children. In hypothyroid 
women, pituitary responsiveness to LHRH is not al-
tered but chronic elevation of basal gonadotropins may 
partially explain the anovulation [3]. Hypothyroidism 
in women is less frequently associated with menstrual 
disturbance, but menstrual irregularities tend to be 
more frequent in severe hypothyroidism [4]. Some 
women with diagnosed hypothyroidism have associa-
ted hyperprolactinemia.
Hyperprolactinemia may cause hypogonadism. 
Overt hypogonadism occurs when prolactin (PRL) is 
significantly increased. GnRH release is suppressed, re-
sulting in low gonadotropin levels. LH pulse frequency 
is decreased, while LH response to GnRH is normal or 
increased [5]. The normalisation of PRL is associated 
with recovering LH pulse frequency and correcting 
hypogonadism.
Mass lesions in the hypothalamus can also affect the 
secretion of GnRH, disrupt the hypothalamic–hypophy-
seal portal circulation and cause hypogonadotropic 
hypogonadism. Such cases usually cause other pituitary 
hormone abnormalities as well. Examples of tumours 
that cause HH are craniopharyngiomas and germ cell 
tumours. Craniopharyngiomas are rare epithelial tu-
mours arising from remnants of the craniopharyngeal 
duct that occur with an annual incidence of 0.13 cases 
per 100,000 person–years. They are histologically benign 
lesions, usually cystic or mixed (84% to 99%). Cranio-
pharyngiomas almost always have a suprasellar com-
ponent and are rarely purely intrasellar. The endocrine, 
visual, and neuropsychological morbidities associated 
with craniopharyngiomas are significant. The frequency 
of individual hormone deficits varies significantly across 
studies (88% to 100% for growth hormone, 80% to 95% 
for FSH and LH, 55% to 88% for adrenocorticotropic 
hormone, 39% to 95% for thyroid-stimulating hormone, 
and 25% to 86% for antidiuretic hormone). Potentially 
more disabling are the consequences of hypothalamic 
damage that occurs so commonly in patients with cra-
niopharyngiomas [6]. Germ cell tumours are believed 
to result from malignant transformation and abnormal 
migration of primordial germ cells. Germ cell tumours 
occur most commonly in the pineal region (50%) and 
in the anterior hypothalamus (30%); these tumours can 
cause hypopituitarism.
Infiltrating diseases which cause hypothalamic 
dysfunction include sarcoidosis, Langerhans cell histio-
cytosis, haemochromatosis, leukaemia, lymphoma and 
Wegener’s granulomatosis. Central infiltrating disease 
is often the presenting feature of the other associated 
hormonal abnormalities. In this article, we present 
a short review of the major causes of acquired HH, but 
most of the above causes of HH will not be discussed 
because they do not fall within the scope of the article.
Idiopathic HH
Idiopathic hypogonadotropic hypogonadism (IHH), 
also called isolated GnRH deficiency, is characterised 
by a failure of initiation of puberty due to insufficient 
gonadotropin release, thus resulting in the failure to 
develop secondary sexual characteristics and a ma-
ture reproductive system. Currently known genetic 
defects account for about 30% of all IHH cases. When 
embryonic migration of GnRH neurons from the nasal 
placode to their final destination in the hypothalamus 
is disrupted, the resulting phenotype is Kallmann 
syndrome (KS), which is clinically characterised by 
hypogonadotropic hypogonadism and anosmia. Nor-
mosmic idiopathic hypogonadotropic hypogonadism 
(nIHH) distinguished from Kallmann syndrome has 
been observed. Both chromosomal abnormalities and 
single gene mutations have been identified in patients 
with IHH and KS [6].The prevalence of cytogenetic 
abnormalities is unknown in IHH/KS patients unless 
they have additional features suggesting a contiguous 
gene deletion syndrome that may be detectable by 
karyotyping.
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Family members with the same genotype may 
display a range of features of the GnRH neurons that 
successfully completed their embryonic journey to the 
hypothalamus. The prevalence of IHH has been esti-
mated at between 1 in 4,000 and 1 in 10,000 males. It is 
reported to be between two and five times less frequent 
in females [7]. The paradigm of this division is to define 
Kallmann syndrome as a form generally combined with 
anosmia. There is substantial variation in clinical expres-
sion of the same genetic defect in families of patients 
with complete anosmia and hypogonadotropic hypogo-
nadism to less severe hypogonadotropic hypogonadism 
manifesting as delayed puberty.
Genetic basis for IHH
The genetic causes of Kallmann syndrome and nIHH 
are summarised in Table I. Some genes (FGFR1, FGF8, 
PROKR2, PROK2, CHD7) have been associated with 
both Kallmann syndrome and nIHH.
Kallmann syndrome 1, caused by mutation in the 
KAL1 gene, is inherited in an X-linked manner. Deletion 
of KAL1 is an extremely rare cause of this syndrome. The 
KAL1 gene encodes an extracellular glycoprotein called 
anosmin-1, which is an adhesion molecule responsible 
for the migration of GnRH neurons and formation of 
the olfactory bulb in the foetal period. This syndrome 
has not been described in women so far.
Kallmann syndromes 2 and 6 are caused by muta-
tions of the FGFR1 (fibroblast growth factor receptor) 
and FGF8 (fibroblast growth factor 8) genes. FGFR1 re-
quires heparin sulphate proteoglycans as co-receptors, 
and anosmin-1. Loss of FGFR1 function has been 
confirmed as producing reproductive abnormalities 
ranging from severe autosomal dominant Kallmann 
syndrome through autosomal dominant, fully penetrant 
nIHH, to delayed puberty.
Approximately 10% of patients with Kallmann syn-
drome have been found to have loss of function muta-
tions in FGFR1. FGF8 mutation patients exhibited vari-
Table I. Genetic defects causing idiopathic hypogonadotropic hypogonadism (IHH). Modified by [28]
Tabela I. Uszkodzenie genetyczne powodujące idiopatyczny hipogonadyzm hipogonadotropowy. Zmodyfikowane przez [28]
Gene Year linked 
to human HH
Syndrome name Phenotypes Inheritance Comment
KAL1 1991 Kallmann syndrome 1 KS X-linked R 70% synkinesia 30% unilateral 
renal agenesis
FGFR1 2003 Kallmann syndrome 2 KS nIHH DA (AR) 
oligogenic
30% Cleft lip/palate common
NELF KSIHH Digenic monogenic
PROKR2 2006 Kallmann syndrome 3 KS nIHH AR AD oligogenic Weak reported association 
with epilepsy, sleep disorder, 
synkinesia, fibrous dysplasia, 
obesity
PROK2 2006 Kallmann syndrome 4 KS nIHH AR AD oligogenic
CHD7 2004 Kallmann syndrome 5 CHARGE syn KS AD Deafness and semicircular canal 
hypoplasia common
FGF8 2008 Kallmann syndrome 6 KS nIHH AD (AR) 
oligogenic
Cleft lip/palate relatively common
GNRHR 1997 nIHH AR oligogenic No accessory features
GNRH1 2009 nIHH AR AD? No accessory features
KISS1R 2003 nIHH AR No accessory features
TAC3 2009 nIHH AR Only 2 patients described to date, 
both with mild learning disability
TACR3 2009 nIHH AR No accessory features
LEP 1997 IHH AR Obesity
LEPR 1998 IHH AR Obesity
NROB1 1994 IHH XLR Adrenal hypoplasia congenital
PCSK1 IHH AR Obesity
KS — Kallmann syndrome; nIHH — normosmic isolated hypogonadotropic hypogonadism; AD — autosomal dominant; AR — autosomal recessive; 
XLR — X-linked recessive
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ous degrees of olfactory function and GnRH function. In 
addition, cleft palate is found in up to 30% of patients, 
while cartilage abnormalities in either ear or nose, and 
some digital anomalies, have been reported [8].
Nasal embryonic LHRH factor (NELF) may play 
a pivotal role in GnRH neuron migration, puberty and 
reproduction. A NELF gene mutation and an FGFR1 mu-
tation have been reported in a family which together 
produced KS, but not NELF by itself [9].
Kallmann syndromes 3 and 4 are caused by 
mutations in the PROKR2 (prokineticin receptor 2) 
and PROK2 (prokineticin 2) genes. Prokineticin 2 is 
an 81-amino acid peptide, which together with its 
receptor has been recognised as a strong candidate for 
failed development of the olfactory bulb and migration 
of GnRH neurons. These syndromes were found in 9% 
of Kallmann syndrome patients, most of them being 
heterozygous; however, homozygous and compound 
heterozygous mutations have also been described. 
Patients with PROK2 or PROKR2 mutations have con-
siderable phenotypic variability ranging from Kallmann 
syndrome to nIHH. A variety of accompanying clinical 
features, including fibrous dysplasia, synkinesia, and 
epilepsy, have been reported in patients with PROK2 
or PROKR2 mutations.
Kallmann syndrome 5 is caused by a mutation of the 
CHD7 gene, which encodes a chromatin-remodelling 
factor (chromodomain helicase DNA-binding protein 7) 
and is defective in CHARGE syndrome. Some patients 
also have IHH and hyposmia. On the basis of the hy-
pothesis that Kallmann syndrome and nIHH may be 
a milder allelic variant of CHARGE syndrome, patients 
diagnosed with hypogonadotropic hypogonadism and 
anosmia should be screened for clinical features con-
sistent with CHARGE syndrome. The term ‘CHARGE 
syndrome’ is used to describe a pattern of birth defects 
in children with coloboma, heart defects, atresia of 
the choanae, retardation of growth and development, 
genital anomaly and ear abnormality. The prevalence 
of CHARGE syndrome is approximately 1 in 10,000, and 
more than 400 patients have now been reported [10]. 
The clinical criteria of CHARGE syndrome are sum-
marised in Table II. GnRH1 and GnRHR gene defects 
cause nIHH. To date, many familial and some sporadic 
cases of GnRHR gene mutation have been reported. 
On the basis of a large series, GnRHR mutations have 
been suggested to account for about 40–50% of familial 
nIHH, and around 17% of sporadic nIHH. In most early 
reports, the GnRHR defects consisted of point mutations 
leading to amino acid substitutions.
Rarer mutations lead to frame-shifts or premature 
stop codons, resulting in a truncated protein, but no 
true GnRHR1 deletions have so far been described [11]. 
The most consistent characteristic of patients with Gn-
RHR mutation is their pituitary resistance to pulsatile 
GnRH administration when the phenotype is severe. 
Pregnancy has been obtained after pulsatile administra-
tion of GnRH. In addition, isolated cases of nIHH have 
presented with pregnancy after the administration of 
clomiphene citrate [7]. The differentiated clinical expres-
sion of GnRHR mutation results in partial loss of the 
GnRHR function, and in one case this was attributed to 
interaction with a mutation in FGFR1, which produces 
different phenotypes [2].
Recently, defects in the GNRH1 gene itself have 
been reported for the first time. Chan et al. [3] reported 
a homozygous mutation in a male patient with severe 
nIHH. This single basepair deletion produces a frame 
shift that is predicted to disrupt the GnRH decapep-
Table II Clinical criteria of CHARGE Syndrome by [10]
Tabela II .  Kr yteria kliniczne zespołu CHARGE. 
Na podstawie [10]
Major criteria
Coloboma of the iris, retina, choroid or disc (75–90%) 
Microphthalmia
Choanal atresia (35–65%)
Ear abnormalities (> 95%): 
— external ear (lop or cup shaped)
— middle ear (ossicular malformations
— chronic serous otitis media)
— inner ear (cochlear defects)
— mixed deafness (60–90%)
Cranial nerve dysfunction: 
— unilateral or bilateral facial palsy
— sensorineural deafness
— swallowing problems
Minor criteria
Hypoplastic genitalia: 
— micropenis and cryptorchidism (80%)
— hypoplastic labia (30–40%)
HH (65–85%)
Developmental delay: 
— delayed motor milestones
— language delay
— learning disability of varying degree
Cardiovascular malformations: 
— conotruncal defect, e.g. Fallot’s tetralogy
— AV canal defects
— aortic valve or arch defects
Growth deficiency: 
— short stature
— GH deficiency
Orofacial cleft (15–20%)
Tracheoesophageal fistula
Characteristic facies
Inclusion rule
4 majors OR 3 majors + 3 minors
HH — hypogonadotropic hypogonadism; GH — growth hormone
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tide. These authors also identified a rare heterozygous 
GnRH1 sequence variant in four patients with nIHH. 
Simultaneously, Bouligand et al. [11] presented isolated 
familial nIHH and GnRH1 mutation. The case reports 
concerned two of four children of non-consanguineous 
parents who were found to have nIHH. Both brother 
and sister showed characteristics of severe nIHH, and 
simultaneously they had a blunted response to GnRH 
bolus administration (100 μg intravenously).
A mutation in the G-protein-coupled receptor GPR 
54 was described in 2003 [14]. GPR 54 had previously 
been shown to be the receptor for a small peptide 
derived from the KISS1 gene (leading to its redesigna-
tion as KISS1R). Before this discovery, some cases of 
familial nIHH had been identified as resulting from 
defects of the short arm of chromosome 19 [15]. Two 
genetic studies, one performed in the USA and the 
other in France, demonstrated that nIHH may be due 
to inactivation of KISS1R [16]. KISS1R mutations are 
a rare cause of nIHH. Individuals with nIHH have been 
shown to have severely reduced LH pulse amplitude, 
but approximately normal pulse frequency. Successful 
pregnancy has been reported after specific stimulation 
of ovulation [17].
Topaloglu et al. [18] reported four human pedi-
grees with severe congenital gonadotropin deficiency 
and pubertal failure in which all affected individuals 
were homozygous for loss of function mutation in 
TAC3 (encoding neurokinin B) or its receptor TACR3 
(encoding neurokinin B receptor). Gianetti et al. [20] 
presented phenotypic information concerning seven 
females with coding sequence variants in TACR3/TAC3. 
None of the females had spontaneous thelarche, and 
five of them demonstrated evidence for reversibility of 
their hypogonadism after discontinuation of therapy. 
Neurokinin B, a member of the substance P related 
tachykinin family, is known to be highly expressed 
in hypothalamic neurons, especially in the actuate 
nucleus, and is co-expressed there with kisspeptin. 
Neurokinin B exerts an influence on reproductive 
function, and its importance in sustaining the integrity 
of the hypothalamic-pituitary-gonadal axis is expected 
to be elucidated over the next few years.
Clinical presentation
Kallmann syndrome may be suspected in a prepubertal 
patient with anosmia, especially when there is already 
a positive family history. Usually, however, a clear pic-
ture of the disorder is revealed in adolescence. Rarely, 
individuals have normal sexual maturation and develop 
IHH in adulthood. The majority of girls can be suspected 
of IHH when pubertal development is incomplete or 
absent after the age of 13. Primary amenorrhea occurs 
in approximately 90% of cases of IHH. Girls before 
puberty have normal stature, but the pubertal growth 
spurt does not occur. Stature retardation is very rare, 
but in contrast the absence of long-bone epiphyseal 
closure explains these patients’ frequent eunuchoid 
aspect and relative tallness. To distinguish nIHH from 
constitutional late puberty can be difficult when these 
reversible forms occur before 20 years of age.
Adult females have little or no breast development, 
although in some patients it may be almost normal. 
Since adrenal maturation proceeds normally, the low 
levels of androgen production in the adrenal glands 
may allow normal onset of pubic hair growth (adre-
narche) and therefore the pubic hair may be absent, 
sparse, or even normal. Partial forms are frequent in 
women, while a very mild form occurs in only a mi-
nority of women. This form of IHH can be revealed 
by isolated chronic anovulation, whereas oestradiol 
secretion is adequate for endometrial development, 
and can be shown by onset of bleeding after progestin 
administration, as well as by oligomenorrhea. These 
attenuated forms have also been described as having 
conceived spontaneously.
Retarded bone maturation, osteopenia and osteopo-
rosis are frequent when the gonadotropin deficiency is 
discovered in adulthood [17].
Establishing the diagnosis
The diagnosis of IHH is established by the presence of 
both suggestive clinical findings and laboratory findings 
consistent with hypogonadotropic hypogonadism, and 
the absence of secondary causes of hypothalamic hy-
pogonadism. The first step of the diagnostic procedure 
is a detailed physical examination with the assessment 
of the development of secondary sexual characteristics, 
and checking family history. Then it is necessary to 
perform a semiquantitative assessment of olfaction to 
detect hyposmia. Examination of the outer ear and hear-
ing is also useful to rule out mild CHARGE syndrome. 
In women without anosmia or hyposmia or identified 
genetic anomalies, the diagnostic procedure should 
exclude eating disorders, excessive physical activity, 
and chronic underlying conditions. Body mass index 
and body fat should also be calculated. Laboratory tests 
should be limited to assessing the levels of LH, FSH, 
PRL and oestradiol. Plasma LH, FSH and oestradiol 
concentrations are often low in women, sometimes 
being near the detection limit. In very mild form, 
which occurs in only a minority of women, nIHH can 
be revealed by isolated chronic anovulation, whereas 
oestradiol secretion is almost normal. The test with 
intravenous administration of 100 μg GnRH provides 
no extra diagnostic information relative to baseline go-
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nadotropin levels, but its outcome reflects the severity 
of the gonadotropin deficiency. 
Layendecker et al. [20] divided gonadotropin defi-
ciency into three degrees of severity on the basis of tests 
with the administration of progesterone, clomiphene 
citrate and GnRH. Patients having degree 3a or 3b have 
a chance of recovery of menstruation and fertility, but 
for patients with degree 3c, the only chance of becoming 
pregnant is after treatment with gonadotropins. The 
diagnostic procedures should also exclude hyperpro-
lactinemia, global anterior pituitary insufficiency and 
an associated endocrine disorder that may be part of 
syndromic forms of IHH.
Magnetic resonance imaging (MRI) of the brain 
and olfactory bulbs is useful in IHH. MRI can rule out 
expansive, infiltrative, or malformative disorders, and 
can also be useful to analyse the olfactory bulbs. Renal 
ultrasound examination should be made in Kallmann 
syndrome, as it can reveal renal malformation or agen-
esis. Pelvic sonography, which is now a routine part 
of gynaecological examination, should always be per-
formed to determine the size of the uterus, endometrial 
thickness and ovary development. In adult women, 
especially those with osteoporotic risk factors, such 
as glucocorticoid treatment and smoking, one should 
consider measuring bone mineral density.
Management
Treatment options for IHH include sex steroids, gonado-
tropins, and pulsatile GnRH administration. The choice 
of therapy is determined by the goal of treatment. The 
majority of young women have a lack of development 
of the secondary sexual characteristics, and they should 
be treated with oestrogens, initially with low doses 
(1 mg/oestradiol p.o.). After approximately six months, 
when breast development has been optimised, replace-
ment doses of oestradiol and progestagens should be 
implemented. In women with nIHH who wish to be-
come pregnant, pulsatile GnRH stimulation can be used. 
Intravenous pulsatile administration of GnRH mimics 
normal cycle dynamics with the resulting ovulation of 
a single follicle [21]. This therapy offers a clear advan-
tage over treatment with exogenous gonadotropins, 
which involves higher rates of both multiple gestation 
and ovarian hyperstimulation syndrome. For either 
approach, however, the rate of conception is approxi-
mately 30% per ovulation cycle [7]. Recently, in nIHH 
women, in order to stimulate ovulation, recombinant 
FSH has commonly been used. Its use provides a low 
risk of hyperstimulation syndrome. But in cases of se-
vere form of IHH at a concentration of LH in the blood 
below 1.2 mIU/ml, it is necessary to add to the therapy 
recombinant hCG, or a preparation containing FSH 
and LH, or recombinant LH, since FSH administration 
itself does not lead to luteinisation of granulosa cells. It 
is also recommended to follow it with administration of 
progesterone to maintain corpus luteum function. This 
therapeutic regimen is assessed to give 70% of pregnan-
cies with the application of six cycles of treatment, but it 
increases the risk of ovarian hyperstimulation syndrome 
and the development of multiple pregnancies.
Nutritional hypothalamic dysfunction
Adaptation of a woman’s body to starvation leads to 
menstrual and fertility disorders. A number of repro-
ductive disorders appear to be related to dieting and 
the desire for leanness. Adolescent girls who present 
with eating disorders before menarche have not only 
lost weight but are also stunted in growth [22]. Girls 
first begin to develop a preoccupation with dieting 
for weight loss and to describe feelings and behaviour 
associated with dieting around the time of menarche. 
This concern is accentuated by the rapid increase in 
height, weight, and body fat that occurs just before 
menarche, but it is also related to a window of vulner-
ability to socio-cultural influences that focus on body 
image and weight. 
Most eating disorders first develop in adolescence, 
with 90% of eating disorders present before the age 
of 25 [22]. In healthy adult women, a short-term calo-
rie restriction diet (800–1,100 kcal/per day) does not 
change the menstrual rhythm. When dietary restric-
tion persists for more than one cycle, it is followed by 
weight loss and suppression of ovulation. Moderate 
dietary restriction and weight loss in normal cyclic 
women are associated with a reduction of oestradiol 
levels in the face of almost normal LH levels, a conse-
quence of which is functional hypothalamic amenor-
rhea (FHA). Severe starvation in healthy women for 
two and half weeks induces a reversal of LH pulses 
to prepubertal patterns [6]. Women with FHA have 
reduced central GnRH drive, resulting in low FSH and 
LH levels, which causes anovulation.
The most serious eating disorders, such as anorexia 
nervosa, bulimia nervosa, and binge eating disorder, 
are classified as psychiatric illnesses, and therefore will 
not be discussed here.
Athletic amenorrhea
The physiological and psychosocial health benefits of 
exercise have been widely promoted by society, but we 
should not forget that intense exercise can cause adverse 
health effects. First described in 1997, the female athletic 
triad is a syndrome that includes disordered eating, 
amenorrhea and osteoporosis. Athletic amenorrhea has 
566
Hypogonadotropic hypogonadism in women Piotr Skałba, Magdalena Guz
SZ
K
O
LE
N
IE
PO
D
Y
PL
O
M
O
W
E
been described in women involved in long-distance 
running, rowing, skiing, high-performance gymnastics, 
volleyball, judo and ballet. It has been found that the 
disorder may affect not only professional sportswomen, 
but also women practicing recreational exercises. In-
tense recreational exercises cause one in three of these 
women to develop ovulatory dysfunction. Female 
athletes are characterised by changes in metabolism in 
the form of intermittent or chronic imbalance due to 
increased energy expenditure or caloric intake. Another 
factor negatively affecting hypothalamic function is 
stress associated with competition and performance. 
Under normal conditions, after acute stress or energy 
demand passes, hormonal equilibrium is restored. 
In contrast, chronic stress can result in alteration of 
hormone secretion, and in particular it may damage 
hypothalamic secretory function. The important role 
played by energy imbalance and psychological factors 
in the pathogenesis of athletic amenorrhea should be 
stressed [23].
Risk factors of athletic amenorrhea are: age below 17 
years, psychological factors and food restrictions. But 
the mechanism most likely to initiate development of 
the disorder is a disparity between the calorie intake 
and energy expenditure. FHA is estimated to affect up 
to 5% of women of reproductive age and is the under-
lying cause of 35% of women seeking evaluation for 
secondary amenorrhea.
This disorder of energy balance reduces the ac-
tivity of the hypothalamic centres responsible for 
the secretion of GnRH. Reduction of central drive 
GnRH results in low FSH and LH levels, which 
causes anovulation. In FHA women, the disruption 
of GnRH drive is also connected to activation of 
the hypothalamic-pituitary-adrenal (HPA) axis, and 
suppression of the hypothalamic-pituitary-thyroidal 
(HPT) axis. Changing functions of the two axes are 
due to the need to mobilise energy in response to 
stress. Other peripheral metabolic factors such as gh-
relin, insulin, leptin and peptide YY also play a role in 
communicating energy status to the brain areas that 
modulate metabolism. Gut peptides and adipocy-
tokines also appear to be altered in exercising women 
with FHA, and have been hypothesised to be involved 
in the etiology of this disorder. Ghrelin is produced 
by cells in the stomach and appears to be a signal of 
disordered eating independent of weight or body fat, 
such that elevated ghrelin may result in continuing 
suppression of the hypothalamic–pituitary–ovarian 
axis with amenorrhea despite normal body fat and 
leptin levels. Eating disorders are also characterised 
by elevations in corticotropin-releasing hormone and 
cortisol, along with loss of the normal circadian rhythm 
of cortisol. Neuropeptide Y is produced by nuclei in 
the hypothalamus and appears to have both stimu-
latory and inhibitory effects on GnRH secretion in 
response to leptin [24]. A critical leptin level threshold 
is suggested to be necessary for regular menses. Ad-
ditionally, in FHA, elevated night-time serum growth 
hormone levels and lower 24 h prolactin levels have 
been observed [25].
A prospective study by Rauh et al. [26] showed that 
high school female athletes with disordered eating and 
oligomenorrhea/amenorrhea have a reduced BMD 
(bone mineral density). A BMD level below the expected 
range for age was associated with musculoskeletal in-
jury. The authors conclude that BMD levels should be 
closely monitored in adolescent female athletes.
Eating disorders and athletic amenorrhea 
treatment
Appropriate intervention depends on determining 
which behaviour needs to be modified. Attention 
should be concentrated on the promotion of psycho-
social harmony, restoring ovulation and menstrual 
cyclicity. Methods that are considered useful include 
a combination of cognitive behaviour therapy with 
relaxation techniques coupled with adequate caloric in-
take. One should avoid extensive workups for physical 
causes when women have a clear fear of fatness, drive 
for thinness, preoccupation with weight, binging and 
purging, or compulsive exercise suggesting an eating 
disorder. The implementation of hormonal therapy 
to regularise menstrual cycles is not indicated when 
the patient is underweight, dieting despite a normal 
weight range, or compulsively exercising. It is advis-
able to prescribe 1,500 mg calcium citrate/400 units 
vitamin D per day in divided doses. Before the plan 
of ovulation stimulation in order to become pregnant, 
a healthy weight should be established. The patient 
should also be educated about the effect of under-
weight on ovulation and risks of eating disorders for 
pregnancy and offspring [22].
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